Clinical utility of flow cytometry in multiple myeloma

Bruno Paiva

At the Myeloma 2015 meeting, Dr Bruno Paiva (University of Navarra, Spain) discusses the utility of flow cytometry as a therapeutic tool to identify precursor cells and detect the presence or absence of minimal residue disease (MRD) in multiple myeloma.

Speaker: Bruno Paiva

Share this video  
Multiple Myeloma
Myeloma 2015
Interview
11th April 2015
More from Bruno Paiva
Assessment of response in MM: challenges and advances
The use of immunophenotyping to assess minimal residual disease (MRD) in multiple myeloma
Next steps for novel treatments in multiple myeloma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals